Algorithm Proposed to Expand Cisplatin Eligibility for MIBC
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Bladder Cancer
BLADDER CANCER ADVISOR
FEATURED CONTENT
-
-
FDA Label Restriction Triggers Increased Uptake of PD-L1 Assays in Urothelial Carcinoma
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays. -
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs. -
Muscle-Invasive Bladder Cancer: The Evolving Treatment Landscape
Patients diagnosed with MIBC are at a significant risk for death — which has not greatly improved in the last few decades.
BLADDER CANCER NEWS
dd-MVAC Regimen ‘Should Be Gold Standard’ for Muscle-Invasive Bladder Cancer
First-Line Immunotherapy, Chemotherapy for mUC of the Bladder Offer Similar Survival
Opdivo Approved as Adjuvant Treatment for High-Risk Urothelial Carcinoma
FDA: No Approval for Bladder Cancer Drug Vicineum
Sacituzumab Govitecan Elicits Responses in Previously Treated Metastatic Urothelial Carcinoma
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
Loading... 
Loading...